-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating
AbCellera Biologics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 77 to 81.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
AbCellera Biologics is not currently near a potential buying area. While it is a low-priced stock, it does trade an average volume of millions of shares each day. As the stock clears key moving averages, see if the stock goes on to form a clear chart pattern that could launch a new move in higher than current trade volume.
The company showed 0% earnings growth last quarter. Sales gains came in at 1,740%.
AbCellera Biologics holds the No. 52 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
YOU MAY ALSO LIKE:
Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith's Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders
IBD Digital: Get access to subscriber-only stock lists and market analysis. Plus, add the weekly print edition for your weekend prep.
AbCellera Biologics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 77 to 81.
Baccelera Biologics 周一,其相对强度(RS)评级出现了积极改善,从77升至81。
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
在寻找最值得买入和关注的股票时,请密切关注相对价格走强。
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
《投资者商业日报》的这项独家评级以1(最差)至99(最好)的分数确定了股价表现。该等级显示了股票在过去 52 周内的价格行为与我们数据库中所有其他股票的比较情况。
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
数十年的市场研究表明,市场最大的赢家在走势的早期阶段的RS评级通常在80以上。
See How IBD Helps You Make More Money In Stocks
看看IBD如何帮助你在股票中赚更多的钱
AbCellera Biologics is not currently near a potential buying area. While it is a low-priced stock, it does trade an average volume of millions of shares each day. As the stock clears key moving averages, see if the stock goes on to form a clear chart pattern that could launch a new move in higher than current trade volume.
Abcellera Biologics目前不在潜在的买入区附近。虽然它是一只低价股票,但它每天的平均交易量为数百万股。随着该股突破关键移动平均线,看看该股能否继续形成清晰的图表模式,从而在高于当前交易量的情况下引发新的走势。
The company showed 0% earnings growth last quarter. Sales gains came in at 1,740%.
该公司上个季度的收益增长为0%。销售额增长了1,740%。
AbCellera Biologics holds the No. 52 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Abcellera Biologics在医疗生物医学/生物技术行业集团的同行中排名第52位。 Genmab ADR 和 Vertex 制药 也是该集团收视率最高的股票之一。
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
值得买入和关注的股票:热门首次公开募股、大盘股和小盘股、成长型股票
YOU MAY ALSO LIKE:
Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith's Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders
你可能还喜欢:
加入 IBD Live,向专业人士学习热门的图表阅读和交易技巧
MarketSmith 的工具可以帮助个人投资者
使用SwingTrader从短期趋势中获利
通过 IBD 排行榜及时获取买入和卖出提醒
与IBD长期领导者一起寻找最佳长期投资
IBD Digital: Get access to subscriber-only stock lists and market analysis. Plus, add the weekly print edition for your weekend prep.
IBD Digital: 访问仅限订阅者的股票清单和市场分析。另外,添加 每周 为周末做准备的印刷版。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧